Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis

Acta Haematologica

Volumn 124, Issue 4, 2010, Pages 206-213

  Lewis, Grant ^a   Hall, Patricia ^a   Eisa, Nihal ^b   Deremer, David ^b   Dobbins, Robin ^a   El Geneidy, Mohamed ^a   Jillella, Anand ^a   Ustun, Celalettin ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute myelogenous leukemia; Antifungal prophylaxis; Fluconazole; High dose cytarabine; Invasive fungal infections

Indexed keywords

ACICLOVIR; CYTARABINE; FLUCONAZOLE; LEVOFLOXACIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; SYSTEMIC MYCOSIS;

ADULT; ANTIFUNGAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CONTINENTAL POPULATION GROUPS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUCONAZOLE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 78149344647     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321504     Document Type: Article

References (48)

1. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM 2004 study. Haematologica 2006; 91: 1068-1075.
2. Kobayashi R, Kaneda M, Sato T, Ichikawa M, Suzuki D, Ariga T: The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol 2008; 30: 886-890.
3. Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT, Nosari A, Candoni A, Bonini A, Mattei D, de Waure C, Fianchi L, Valentini CG, Aversa F, Leone G, Pagano L: Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hematopoietic stem cell transplant: who is at highest risk? Eur J Haematol 2008; 81: 242-243.
4. Muhlemann K, Wenger C, Zenhausern R, Tauber MG: Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545-550.
5. Marr KA, Carter RA, Boeckh M, Martin P, Corey L: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
6. Kaya Z, Gursel T, Kocak U, Aral YZ, Kalkanci A, Albayrak M: Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470-475.
7. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Steven N, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Donald Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
8. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, Klis B, Counts GW, Meyers JD: Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
9. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA: Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-351.
10. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L: Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev 2010; 24: 51-61.
11. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W: Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004; 50: 197-222.
12. Groll AH, Tragiannidis A: Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46: 212-229.
13. Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, Aloisi T, Irrera G, Bonini A, Picardi M, Caramatti C, Invernizzi R, Mattei D, Melillo L, de Waure C, Reddiconto G, Fianchi L, Valentini CG, Girmenia C, Leone G, Aversa F: Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-1170.
14. Wingard JR: New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol. 2007; 20: 99-107.
15. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N: Randomized placebo- controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-340.
16. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomizedcontrolled clinical trials. Cancer 2002; 94: 3230-3246.
17. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, Matsuyama T, Takezako N, Miwa A, Kern W, Kami M, Akiyama H, Hirai H, Togawa A: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
18. Glasmacher A, Prentice AG: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56(suppl 1):i23-i32
19. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-5489.
20. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky- Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH: Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-147.
21. Vardakas KZ, Michalopoulos A, Falagas ME: Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a metaanalysis of randomized-controlled trials. Br J Haematol 2005; 131: 22-28.
22. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW: Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-1312.
23. Rex JH, Anaissie EJ, Boutati E, Estey E, Kantarjian H: Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia 2002; 16: 1197-1199.
24. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. Nsoh Engl J Med 2007; 356: 348-359.
25. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ: Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies: recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-122.
26. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS: Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6: 122-174.
27. Riley LC, Hann JM, Weatley K, Stevens RF: Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10). Br J Haematol 1999; 106: 436-444.
28. Taylor S: MIDAC: consolidation chemotherapy for AML. 2008. . uk/healthcare-professionals/clinical-policies- and-protocols/haematology- protocols/ acute-myeloid-leukaemia-aml/MIDAC.pdf.
29. Potter M, Doneely JP: The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol 2004; 111: 175-180.
30. Palmieri S, Sebastio L, Mele G, Annunziata M, Annunziata S, Copia C, Viola A, De Simone M, Pocali B, Schiavone EM, Ferrara F: High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8; 21). Leuk Res 2002; 26: 539-543. (Pubitemid 34462167)
31. Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, Jäger U, Fonatsch C, Kyrle PA, Valent P, Lechner K, Sperr WR: High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res 2005; 29: 609-615.
32. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer: Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
33. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841-2851.
34. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717. (Pubitemid 26068888)
35. Bow EJ, Loewen R, Cheang MS, Schacter B: Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 361-369.
36. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol2000; 110: 273-284.
37. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia - Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671-1677.
38. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients ( 1 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
39. Löwenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WL: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15:3496-3506.
40. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T, EORTC/ GIMEMA Leukemia Group: Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
41. Harousseau JL, Witz B, Lioure B, Hunault- Berger M, Desablens B, Delain M, Guilhot F,Le Prise PY, Abgrall JF, Deconinck E, Guyotat D, Vilque JP, Casassus P, Tournilhac O, Audhuy B, Solary E: Granulocyte colonystimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-787.
42. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A,O'Brien C, Matcham J, Barge A: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710-4718.
43. Motoji T, Okada M, Takanashi M, Oshimi K, Mizoguchi H: Abolition of suppressive effect of acute myeloid leukemia cells on normal granulocyte-macrophage colony formation induced by interleukin-5 associated with eosinophilic cell induction. Leuk Lymphoma 1995; 18: 171-178.
44. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-456.
45. Ustun C, Farrow S, DeRemer D, Fain H, Jillella AP: Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 807-808.
46. Laverdière M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, Moghaddam N: Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. J Antimicrob Chemother 2000; 46: 1001-1008.
47. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 452-429.
48. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.